Specialty Hub

In-depth learning materials and relevant resources by areas of interest.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

In this section

Cardiology

Assorted resources on conditions connected to Cardiology.

Dermatology

Latest information on diseases in Dermatology.

Endocrinology

A detailed look at conditions connected to Endocrinology.

Gastroenterology and Hepatology

In-depth material on Gastroenterology and Hepatology.

Haematology

Assorted resources on conditions connected to Haematology.

Immunology

Immunology, the immune system and immune-mediated diseases.

Infectious Diseases

A detailed look at conditions connected to Infectious Diseases.

Neurology (CNS) and Pain

Learning materials and guidelines on Neurology (CNS) and Pain.

Oncology

A detailed look at conditions connected to Oncology.

Ophthalmology

Assorted resources on conditions connected to Ophthalmology.

Respiratory

In-depth material on Respiratory conditions.

Rheumatology

Latest information on diseases in Rheumatology.

Urology

Learning materials and guidelines on Urology.

Latest news

Drug news

Agios submits NDA to the FDA for mitapivat for treatment of adults with pyruvate kinase deficiency.

-Agios Pharmaceuticals, Inc.a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that it has submitted a New Drug Application (NDA) for mitapivat (AG 348) to the FDA for the treatment of adults with pyruvate kinase (PK) deficiency.

1 mins

Drug news

Koselugo approved in the EU for children with neurofibromatosis type 1 and plexiform neurofibromas. - AstraZeneca + Merck Inc.

AstraZeneca and MSD's Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above.

1 min

Drug news

GSK and Vir Biotechnology announce continuing progress of the COMET clinical development programme for sotrovimab for COVID 19.

GlaxoSmithKline plc and Vir Biotechnology, Inc.announced final, confirmatory results from the Phase III COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) trial demonstrating that sotrovimab, an investigational SARS-CoV-2 monoclonal antibody, significantly reduced the risk of hospitalisation or death among high-risk adult outpatients with mild-to-moderate COVID-19.

2 min

See all news

You may be interested in...

Journal

Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer

Purpose: Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a poor prognosis and an unmet need for effective treatment, especially for patients without BRAF mutations or NTRK or RET fusions.

Journal

Associations between artificial light at night and risk for thyroid cancer: A large US cohort study

Light at night (LAN) inhibits nighttime secretion of melatonin and may cause circadian disruption, which may be a risk factor for cancer. Recent studies have linked high LAN exposure with elevated breast cancer risk.

Journal

Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019

Objective: To evaluate rates of OS in patients with ATC over the last 2 decades.